SEC Form 4 · accession 0001866154-26-000004
Lyell Immunopharma, Inc. · LYEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen J. Hill
Officer — Chief Operating Officer
Period of report
Aug 10, 2026
Accepted (ET)
Aug 11, 2026 · 4:18 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001806952
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 10, 2026 | S | 89 | $14.34 | D | 17,805 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
- F2The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.27 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.